1. Novel Approaches to T1D Management

3. Unmet Needs in Type 1 Diabetes

4. Severe Hypoglycemia From T1D Exchange

5. DKA Risk in People With T1D

6. Adjunctive Therapies for People With T1D

7. Insulin Distribution in Normal Physiology

8. Administration of Exogenous Insulin

9. Purpose of Adjunctive Therapies in T1D

10. ADJUNCT ONE Trial Liraglutide Added to Insulin in T1D

11. Inhibition of SGLT Cotransporters is Effective in Treating T1D

12. Sotagliflozin inTandem Clinical Program in People With T1D

13. Sotagliflozin inTandem1/inTandem2 CGM Substudy Pooled Analysis Trial Design

14. Sotagliflozin inTandem1/inTandem2 Pooled Analysis HbA1c Change From Baseline Weeks 24 and 52

15. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Body Weight Change From Baseline Weeks 24 and 52

16. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Total Daily, Daily Basal, and Daily Bolus Insulin at Week 52

17. Sotagliflozin inTandem1/inTandem2 CGM Substudy Pooled Analysis: Time Spent in Glycemic Ranges

18. Sotagliflozin inTandem1/inTandem2 Pooled Analysis AEs at Week 52

19. Comparison of Rates of DKA in DEPICT-1 and inTandem3 Trials

20. DEPICT-1 and DEPICT-2 (Dapagliflozin) Study Design

21. Key Demographics and Baseline Characteristics

22. DEPICT-1 and DEPICT-2 Mean Change in HbA1c

23. DEPICT-1 and DEPICT-2 Mean Percent Change in Total Daily Insulin Dose

24. DEPICT-1 and DEPICT-2 Mean Percent Change in Total Body Weight

25. DEPICT-1: Proportion of Patients with HbA1c Reduction ≥ 0
DEPICT-1: Proportion of Patients with HbA1c Reduction ≥ 0.5% Without Severe Hypoglycemia

26. CGM Endpoints Pooled Data from DEPICT-1 and 2 over 24 Weeks

27. Safety of Dapagliflozin in People With T1D AEs and Adjudicated DKA

28. EASE 1-3 (Empagliflozin) Trials

29. Risk Mitigation Strategies for DKA

30. Abbreviations

31. Abbreviations (cont)